Repligen - RGEN Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RGEN shares.
View RGEN analyst ratings or view top-rated stocks.

7 equities research analysts have issued 1 year target prices for Repligen's shares. Their RGEN share price forecasts range from $180.00 to $275.00. On average, they anticipate the company's stock price to reach $224.14 in the next twelve months. This suggests a possible upside of 16.2% from the stock's current price.
View analysts price targets for RGEN or view top-rated stocks among Wall Street analysts.

Repligen's stock was trading at $169.31 at the beginning of the year. Since then, RGEN stock has increased by 13.9% and is now trading at $192.91.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our RGEN earnings forecast.

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings results on Thursday, October, 28th. The biotechnology company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.14. The biotechnology company earned $178.22 million during the quarter, compared to analyst estimates of $163.97 million. Repligen had a net margin of 20.76% and a trailing twelve-month return on equity of 10.98%. The company's revenue for the quarter was up 89.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.40 earnings per share.

Repligen issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $3.15-$3.20 for the period, compared to the consensus estimate of $3.20. The company issued revenue guidance of $795.00 million-$805.00 million, compared to the consensus revenue estimate of $803.99 million.

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

Repligen's stock is owned by many different retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (1.23%), Stephens Investment Management Group LLC (0.98%), Pendal Group Ltd (0.84%), New York State Common Retirement Fund (0.78%), Allspring Global Investments Holdings LLC (0.54%) and Sumitomo Mitsui Trust Holdings Inc. (0.24%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, John Cox, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends.

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RGEN stock can currently be purchased for approximately $192.91.

Repligen (NASDAQ:RGEN) has a market capitalization of $10.71 billion and generates $670.53 million in revenue each year. The biotechnology company earns $128.29 million in net income (profit) each year or $2.90 on an earnings per share basis.

The company employs 1,852 workers across the globe.

Repligen's mailing address is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. The official website for the company is www.repligen.com. The biotechnology company can be reached via phone at (781) 250-0111, via email at investors@repligen.com, or via fax at 781-250-0115.